51 related articles for article (PubMed ID: 29324537)
1. The FIGO Stage IVA Versus IVB of Ovarian Cancer: Prognostic Value and Predictive Value for Neoadjuvant Chemotherapy.
Tajik P; van de Vrie R; Zafarmand MH; Coens C; Buist MR; Vergote I; Bossuyt PMM; Kenter GG
Int J Gynecol Cancer; 2018 Mar; 28(3):453-458. PubMed ID: 29324537
[TBL] [Abstract][Full Text] [Related]
2. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).
Reuss A; du Bois A; Harter P; Fotopoulou C; Sehouli J; Aletti G; Guyon F; Greggi S; Mosgaard BJ; Reinthaller A; Hilpert F; Schade-Brittinger C; Chi DS; Mahner S
Int J Gynecol Cancer; 2019 Oct; 29(8):1327-1331. PubMed ID: 31420412
[TBL] [Abstract][Full Text] [Related]
3. Expanding the Use of HIPEC in Ovarian Cancer at Time of Interval Debulking Surgery to FIGO Stage IV and After 6 Cycles of Neoadjuvant Chemotherapy: A Prospective Analysis on Perioperative and Oncologic Outcomes.
Ghirardi V; Trozzi R; Scanu FR; Giannarelli D; Santullo F; Costantini B; Naldini A; Panico C; Frassanito L; Scambia G; Fagotti A
Ann Surg Oncol; 2024 May; 31(5):3350-3360. PubMed ID: 38411761
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and the role of primary debulking in operable stage IVB ovarian cancer with supraclavicular lymph node metastasis: a retrospective study in Chinese patients.
Quan C; Chen X; Wen H; Wu X; Li J
BMC Cancer; 2024 May; 24(1):565. PubMed ID: 38711015
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Chemotherapy Versus Primary Debulking Surgery in FIGO Stage III and IV Epithelial Ovarian, Tubal or Peritoneal Cancer: A Systematic Review and Meta-Analysis.
Tzanis AA; Iavazzo C; Hadjivasilis A; Tsouvali H; Antoniou GΑ; Antoniou SA
Oncol Rev; 2022; 16():10605. PubMed ID: 36531160
[No Abstract] [Full Text] [Related]
6. Developing a novel image marker to predict the clinical outcome of neoadjuvant chemotherapy (NACT) for ovarian cancer patients.
Zhang K; Abdoli N; Gilley P; Sadri Y; Chen X; Thai TC; Dockery L; Moore K; Mannel RS; Qiu Y
Comput Biol Med; 2024 Apr; 172():108240. PubMed ID: 38460312
[TBL] [Abstract][Full Text] [Related]
7. Survival impact of bowel resection in patients with FIGO stage II-IV ovarian cancer.
Wang QM; Xiao Y; Liu YX; Wei X; Gu QY; Linghu H; Liu B
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14843-14852. PubMed ID: 37597026
[TBL] [Abstract][Full Text] [Related]
8. Optimal Management for Stage IVB Endometrial Cancer: A Systematic Review.
Capozzi VA; Scarpelli E; De Finis A; Rotondella I; Scebba D; Gallinelli A; Montrucchio C; Martignon G; Leotta M; Ghi T; Berretta R
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958299
[TBL] [Abstract][Full Text] [Related]
9. Does Operable Stage IV Gingivobuccal Cancers Need Further Prognostic Subgrouping?
Jain S; Pradhan S; Kannan R; Mokal S; Khanapure S; Doctor A
Indian J Otolaryngol Head Neck Surg; 2022 Oct; 74(Suppl 2):2311-2318. PubMed ID: 36452730
[TBL] [Abstract][Full Text] [Related]
10. Survival benefits from concomitant chemoradiotherapy before radical surgery in stage IVA sinonasal mucosal melanoma?
Hafström A; Brun E; Persson S; Sjövall J; Wahlberg P; Greiff L
Laryngoscope Investig Otolaryngol; 2019 Dec; 4(6):624-631. PubMed ID: 31890880
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients.
Vici P; Pizzuti L; Di Lauro L; Conti L; Mandoj C; Antenucci A; Digiesi G; Sergi D; Amodio A; Marchetti P; Sperati F; Valle M; Garofalo A; Vizza E; Corrado G; Vincenzoni C; Tomao F; Kayal R; Marsella A; Carosi M; Antoniani B; Giordano A; Maugeri-Saccà M; Barba M
J Cancer; 2016; 7(5):516-22. PubMed ID: 26958087
[TBL] [Abstract][Full Text] [Related]
12. Therapy-related myeloid neoplasms after treatment for ovarian cancer: A retrospective single-center case series.
Matsuoka A; Tate S; Nishikimi K; Otsuka S; Usui H; Tajima S; Habu Y; Nakamura N; Okuya R; Katayama E; Shozu M; Inaba Y; Koga K
J Obstet Gynaecol Res; 2024 Apr; ():. PubMed ID: 38634254
[TBL] [Abstract][Full Text] [Related]
13. Are Older Patients with Cervical Cancer Managed Differently to Younger Patients? An International Survey.
Frelaut M; De Glas N; Zapardiel I; Kaidar-Person O; Kfoury M; You B; Banerjee S; Brain E; Falandry C; Rodrigues M
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31817566
[TBL] [Abstract][Full Text] [Related]
14. Correction: Outcomes associated with treatment to all sites of disease in patients with stage IVB cancer of the cervix.
Int J Gynecol Cancer; 2023 Oct; 33(10):1673. PubMed ID: 37783483
[No Abstract] [Full Text] [Related]
15. Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer.
Crispin-Ortuzar M; Woitek R; Reinius MAV; Moore E; Beer L; Bura V; Rundo L; McCague C; Ursprung S; Escudero Sanchez L; Martin-Gonzalez P; Mouliere F; Chandrananda D; Morris J; Goranova T; Piskorz AM; Singh N; Sahdev A; Pintican R; Zerunian M; Rosenfeld N; Addley H; Jimenez-Linan M; Markowetz F; Sala E; Brenton JD
Nat Commun; 2023 Oct; 14(1):6756. PubMed ID: 37875466
[TBL] [Abstract][Full Text] [Related]
16. A retrospective analysis for investigating the relationship between FIGO stage IVA/IVB and cytoreductive surgery with prognosis in epithelial ovarian cancer.
Liu H; Luo M; Peng C; Huang J; Wang D; Huang J; Zhang G
Front Oncol; 2023; 13():1103357. PubMed ID: 37564940
[TBL] [Abstract][Full Text] [Related]
17. Survival Outcomes of Patients with International Federation of Gynecology and Obstetrics Stage IV Ovarian Cancer: Cytoreduction Still Matters.
Xiao Y; Linghu H
Cancer Control; 2023; 30():10732748231159778. PubMed ID: 36815671
[TBL] [Abstract][Full Text] [Related]
18. A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer.
Métairie M; Benoit L; Koual M; Bentivegna E; Wohrer H; Bolze PA; Kerbage Y; Raimond E; Akladios C; Carcopino X; Canlorbe G; Uzan J; Lavoué V; Mimoun C; Huchon C; Koskas M; Costaz H; Margueritte F; Dabi Y; Touboul C; Bendifallah S; Ouldamer L; Delanoy N; Nguyen-Xuan HT; Bats AS; Azaïs H
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765667
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Omics Data Reveals Nucleotide Excision Repair-Related Genes Signature in Highly-Grade Serous Ovarian Cancer to Predict Prognosis.
Dai D; Li Q; Zhou P; Huang J; Zhuang H; Wu H; Chen B
Front Cell Dev Biol; 2022; 10():874588. PubMed ID: 35769257
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
